Cargando…

Development and validation of an LC–MS/MS method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (PFASs) in human plasma, including HFPO-DA, DONA, and cC6O4

Per- and polyfluoroalkyl substances (PFASs) include persistent organic pollutants whose spread is still ubiquitous. Efforts to substitute substances of high concern with fluorinated alternatives, such as HFPO-DA (GenX), DONA (ADONA), and cC6O4, have been made. The aim of this work was to develop and...

Descripción completa

Detalles Bibliográficos
Autores principales: Frigerio, Gianfranco, Cafagna, Simone, Polledri, Elisa, Mercadante, Rosa, Fustinoni, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760233/
https://www.ncbi.nlm.nih.gov/pubmed/34907451
http://dx.doi.org/10.1007/s00216-021-03762-1
_version_ 1784633272470339584
author Frigerio, Gianfranco
Cafagna, Simone
Polledri, Elisa
Mercadante, Rosa
Fustinoni, Silvia
author_facet Frigerio, Gianfranco
Cafagna, Simone
Polledri, Elisa
Mercadante, Rosa
Fustinoni, Silvia
author_sort Frigerio, Gianfranco
collection PubMed
description Per- and polyfluoroalkyl substances (PFASs) include persistent organic pollutants whose spread is still ubiquitous. Efforts to substitute substances of high concern with fluorinated alternatives, such as HFPO-DA (GenX), DONA (ADONA), and cC6O4, have been made. The aim of this work was to develop and validate an isotopic dilution liquid chromatography-tandem mass spectrometry (LC–MS/MS) method suitable to quantify 30 PFASs in human plasma. Analytes included legacy PFASs (PFOA, PFOS, and PFHxS), fluorinated alternatives (PFBA, PFBS, 6:2 FTSA, HFPO-DA, DONA, and cC6O4), and newly identified compounds (F-53B and PFECHS). The sample preparation was rapid and consisted of simple protein precipitation and centrifugation. Calibration standards and quality control solutions were prepared with a human pooled plasma containing relatively low background levels of the considered analytes. A complete validation was carried out: the lower limits of quantitation (LLOQs) ranged from 0.009 to 0.245 µg/L; suitable linearity (determination coefficients, R(2) 0.989–0.999), precision (2.0–19.5%, relative standard deviation), and accuracy (87.9–113.1% of theoretical) were obtained for considered concentration ranges. No significant variations of analyte responses were recorded under investigated storage conditions and during matrix effect tests. The external verification confirmed the accuracy of the method, although limited to 12 analytes. The method was also applied to 38 human plasma samples to confirm its applicability. The developed assay is suitable for large-scale analyses of a wide range of legacy and emerging PFASs in human plasma. To our knowledge, this is the first published method including cC6O4 for human biomonitoring. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00216-021-03762-1.
format Online
Article
Text
id pubmed-8760233
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-87602332022-01-26 Development and validation of an LC–MS/MS method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (PFASs) in human plasma, including HFPO-DA, DONA, and cC6O4 Frigerio, Gianfranco Cafagna, Simone Polledri, Elisa Mercadante, Rosa Fustinoni, Silvia Anal Bioanal Chem Research Paper Per- and polyfluoroalkyl substances (PFASs) include persistent organic pollutants whose spread is still ubiquitous. Efforts to substitute substances of high concern with fluorinated alternatives, such as HFPO-DA (GenX), DONA (ADONA), and cC6O4, have been made. The aim of this work was to develop and validate an isotopic dilution liquid chromatography-tandem mass spectrometry (LC–MS/MS) method suitable to quantify 30 PFASs in human plasma. Analytes included legacy PFASs (PFOA, PFOS, and PFHxS), fluorinated alternatives (PFBA, PFBS, 6:2 FTSA, HFPO-DA, DONA, and cC6O4), and newly identified compounds (F-53B and PFECHS). The sample preparation was rapid and consisted of simple protein precipitation and centrifugation. Calibration standards and quality control solutions were prepared with a human pooled plasma containing relatively low background levels of the considered analytes. A complete validation was carried out: the lower limits of quantitation (LLOQs) ranged from 0.009 to 0.245 µg/L; suitable linearity (determination coefficients, R(2) 0.989–0.999), precision (2.0–19.5%, relative standard deviation), and accuracy (87.9–113.1% of theoretical) were obtained for considered concentration ranges. No significant variations of analyte responses were recorded under investigated storage conditions and during matrix effect tests. The external verification confirmed the accuracy of the method, although limited to 12 analytes. The method was also applied to 38 human plasma samples to confirm its applicability. The developed assay is suitable for large-scale analyses of a wide range of legacy and emerging PFASs in human plasma. To our knowledge, this is the first published method including cC6O4 for human biomonitoring. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00216-021-03762-1. Springer Berlin Heidelberg 2021-12-15 2022 /pmc/articles/PMC8760233/ /pubmed/34907451 http://dx.doi.org/10.1007/s00216-021-03762-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Paper
Frigerio, Gianfranco
Cafagna, Simone
Polledri, Elisa
Mercadante, Rosa
Fustinoni, Silvia
Development and validation of an LC–MS/MS method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (PFASs) in human plasma, including HFPO-DA, DONA, and cC6O4
title Development and validation of an LC–MS/MS method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (PFASs) in human plasma, including HFPO-DA, DONA, and cC6O4
title_full Development and validation of an LC–MS/MS method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (PFASs) in human plasma, including HFPO-DA, DONA, and cC6O4
title_fullStr Development and validation of an LC–MS/MS method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (PFASs) in human plasma, including HFPO-DA, DONA, and cC6O4
title_full_unstemmed Development and validation of an LC–MS/MS method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (PFASs) in human plasma, including HFPO-DA, DONA, and cC6O4
title_short Development and validation of an LC–MS/MS method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (PFASs) in human plasma, including HFPO-DA, DONA, and cC6O4
title_sort development and validation of an lc–ms/ms method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (pfass) in human plasma, including hfpo-da, dona, and cc6o4
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760233/
https://www.ncbi.nlm.nih.gov/pubmed/34907451
http://dx.doi.org/10.1007/s00216-021-03762-1
work_keys_str_mv AT frigeriogianfranco developmentandvalidationofanlcmsmsmethodforthequantitationof30legacyandemergingperandpolyfluoroalkylsubstancespfassinhumanplasmaincludinghfpodadonaandcc6o4
AT cafagnasimone developmentandvalidationofanlcmsmsmethodforthequantitationof30legacyandemergingperandpolyfluoroalkylsubstancespfassinhumanplasmaincludinghfpodadonaandcc6o4
AT polledrielisa developmentandvalidationofanlcmsmsmethodforthequantitationof30legacyandemergingperandpolyfluoroalkylsubstancespfassinhumanplasmaincludinghfpodadonaandcc6o4
AT mercadanterosa developmentandvalidationofanlcmsmsmethodforthequantitationof30legacyandemergingperandpolyfluoroalkylsubstancespfassinhumanplasmaincludinghfpodadonaandcc6o4
AT fustinonisilvia developmentandvalidationofanlcmsmsmethodforthequantitationof30legacyandemergingperandpolyfluoroalkylsubstancespfassinhumanplasmaincludinghfpodadonaandcc6o4